NCT00596830_2A: NCT00596830, figure 2A

NCT00596830_2AR Documentation

NCT00596830, figure 2A

Description

Kaplan-Meier digitized data from NCT00596830, figure 2A (PMID 24888810). A reported sample size of 681 for a primary endpoint of OS in lung cancer.

Usage

NCT00596830_2A

Format

A data frame of 681 observations and 3 variables:

time event time (in months)
event OS event indicator (0: no event, 1: event)
arm treatment arms (control, figitumumab)

Source

Langer CJ, Novello S, Park K, et al. Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer. J Clin Oncol 2014; 32: 2059–66.

Examples

summary(NCT00596830_2A)

kmplot(NCT00596830_2A)

raredd/kmdata documentation built on June 15, 2025, 9:33 a.m.